The Garvan Institute of Medical Research became an autonomous research institute in 1984. Sponsored research accounts for one-quarter of Garvan's $14 million 1998 operating income. Going forward, it expects its income to derive approximately one-third from grants, one-third from donations, and one third from commercial activities. The bulk of current revenues from commercial activities come from Eli Lilly, Bristol-Myers, and Merck & Co.